ProCE Banner Activity

ACE-LY-004: Phase II Trial of BTK Inhibitor Acalabrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Slideset Download
Conference Coverage
In patients with R/R MCL, acalabrutinib monotherapy was associated with an ORR of 81% and ongoing responses at 12 months in 72% of these patients.

Released: December 11, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology